Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Alhajahjeh A, Patel KK, Shallis RM, Podoltsev NA, et al. Leuk Lymphoma 2025;66:488-496.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Alhajahjeh A, Patel KK, Shallis RM, Podoltsev NA, et al. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leuk Lymphoma 2025;66:488-496.
PMID: 39560957